Chronic pain, defined as pain existing for >4-6 weeks, affects >60% of patients with autosomal-dominant polycystic disease (ADPKD). It can have various causes, indirectly or directly related to the increase in kidney and liver volume in these patients. Chronic pain in ADPKD patients is often severe, impacting physical activity and social relationships, and frequently difficult to manage. This review provides an overview of pathophysiological mechanisms that can lead to pain and discusses the sensory innervation of the kidneys and the upper abdominal organs, including the liver. In addition, the results of a systematic literature search of ADPKD-specific treatment options are presented. Based on pathophysiological knowledge and evidence derived from the literature an argumentative stepwise approach for effective management of chronic pain in ADPKD is proposed.
I N T R O D U C T I O N
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common renal hereditary disorder, with an estimated prevalence of 1 per 1000 subjects in the general population [1] . Development of renal function decline is the main threat for patients with ADPKD, often leading to end-stage renal disease between the fourth and seventh decade of life [1] . Pain is one of the other debilitating complications [2] .
Pain in ADPKD is classified as acute or chronic. Acute severe pain is relatively uncommon. Data from the TEMPO 3:4 trial suggest an average incidence of clinically significant pain episodes of 7 per 100 person years in untreated patients [3, 4] . In contrast, chronic pain is very common in patients with ADPKD with an estimated prevalence of 60% [5, 6] . A subanalysis of the TEMPO 3:4 trial shows that chronic pain in ADPKD patients with retained renal function is often severe and leads to use of pharmacological agents in 28.0%, sleep disturbances in 16.8% and impacts physical activity and relationships with others in 20.8% [3, 4] . Similar findings were observed in the HALT trial [6] . Thus, chronic pain has major effects on physical and social functioning in patients with ADPKD.
Chronic pain in ADPKD can have various causes and is often difficult to manage. In this review we give an overview of pathophysiological mechanisms that can lead to pain and discuss the sensory innervation of abdominal organs (including the kidneys and the liver). In addition, we present the results of a systematic literature search of ADPKD-specific treatment options. Based on pathophysiological considerations and evidence derived from the literature we propose an argumentative stepwise approach for the effective management of chronic pain in ADPKD.
PAT H O P H Y S I O LO GY O F PA I N I N A D P K D

Acute pain
Acute pain in ADPKD patients can be ADPKD related, or arise from other sources as in any patient. Specific for ADPKD are among others cyst haemorrhage, cyst rupture, cyst infection and urinary tract stone formation.
Neovascularization within cysts, due to angiogenesis promoted by vascular endothelial growth factor, may be involved in renal and liver cyst haemorrhages [7] . Symptomatic episodes probably underestimate the true frequency of cyst haemorrhage. More than 90% of patients with ADPKD have renal cysts with a high signal on magnetic resonance imaging (MRI), indicative for blood or high protein content, whereas only a minority of these patients had been clearly symptomatic [8] . Haematuria is not always a feature of renal cyst haemorrhage. In one study, haematuria was only present in 14 of the 24 patients with pain and evidence of a cyst haemorrhage on computed tomography (CT)-scan [9] . Spontaneous renal cyst ruptures are uncommon, but traumatic and infection-related ruptures of renal cysts into the pyelocalyceal system and the retroperitoneum have been reported [10, 11] . Acute pain in ADPKD can also be related to liver cysts. A retrospective cohort study in 34 ADPKD patients with polycystic livers showed a prevalence of 11.8% haemorrhages and 11.8% ruptures in liver cysts [12] . Typically, these complications occur more frequently in patients with severe hepatomegaly [13] . The acute onset of pain in ADPKD patients with cyst haemorrhage is probably caused by stretching of the renal and liver capsule, although evidence for this is formally lacking.
A history of upper urinary tract infections is seen in 60% of all ADPKD patients, with a higher prevalence in women [14] . The episodes of isolated cyst infection were more frequent than those of acute or chronic pyelonephritis [14] . Liver cyst infections have been described in 5.9% of ADPKD patients [12] . In an ADPKD patient with acute abdominal pain and fever, the diagnosis of cyst infection can be made by fluordeoxyglucose position emission tomography (FDG-PET). The greatest advantage of FDG-PET over conventional CT and MRI is the good spatial discrimination of FDG-PET, which may guide invasive interventions and the evaluation of adjacent tissue [15] . Since discrimination between renal and liver cyst infections is not possible using clinical findings, FDG-PET can assist in establishing the diagnosis by localizing the infection [16] .
Patients with ADPKD have an increased risk for kidney stones, with a prevalence of ∼8-36% [17] [18] [19] . The cause of stone formation is multifactorial and may result from structural abnormalities secondary to cyst growth that lead to urinary stasis, but also from concomitant metabolic disorders. Uric acid is usually the main component of these stones followed by oxalate stones [18] . In fact, the prevalence of hypercalciuria, hyperuricosuria and hypocitraturia is lower in ADPKD with stones compared with ADKPD patients without stones [18, 20] . Surgical management of renal stones is not affected by the underlying (renal) disorder and medical management will be dictated by stone composition [21] .
The management of acute pain in ADPKD patients is beyond the scope of the present review, which focuses on the treatment of chronic pain. However, it should be noted that episodes of acute pain may lead up to the development of chronic pain. The exact mechanism underlying this association is still unknown, but may be due to sensitization [8] . Timely and adequate management of acute pain in ADPKD patients is therefore indicated.
Chronic pain
When pain is present during a period >4 to 6 weeks it is classified as chronic pain. In ADPKD chronic pain can have several causes. Non-ADPKD related causes, such as irritable bowel syndrome, inflammatory bowel disease and gynecological pathology in females, must be ruled out, especially in patients with relatively small kidneys and liver. Chronic pain may bear a direct relation with ADPKD or not. Indirect associations between ADPKD and chronic pain are seen especially in patients with a severe increase in renal and liver volume. The increased abdominal mass may cause musculoskeletal pain, for instance low back pain, because subjects develop an aberrant posture similar to pregnant women. Remarkably, a recent subanalysis from the HALT study showed among patients with an eGFR >60 mL/min × 1.73 m 2 that total kidney volume corrected for height was not related to the frequency or intensity of back, abdominal or radicular pain [6] . Chronic pain directly related to ADPKD is caused by cyst growth induced distension of renal and hepatic capsules or by compression of adjacent tissue [22] .
Pain due to renal cysts is typically located abdominally rather than in the low back area, and described from steady nagging discomfort to a dull aching or severe stabbing pain [4, 22] . Lying on bed is often the most comfortable position, whereas standing, walking and sitting for a long period of time can induce pain [22] . Usually there is no relationship with defecation or micturition, whereas deep inspiration may induce an increase in pain intensity, suggesting a visceral component.
Hepatic cysts are very common in patients with ADPKD, with an overall prevalence of 83% in the age group of 18-46 years [23] . Most hepatic cyst patients are asymptomatic, but those with more severe liver enlargement may experience abdominal fullness or discomfort, gastrointestinal symptoms and nagging or stabbing pain either by compression of adjacent abdominal and thoracic organs or by distension of the hepatic capsule [2] . Furthermore, some of these patients develop chronic shoulder pain due to irritation or tension of the diaphragm. When renal and liver cysts co-exist, the primary source of pain may be difficult to determine.
Chronic pain has also been shown to have negative consequences with respect to anxiety and depression, of which the prevalence is higher in ADPKD patients than in the general population [24] . Furthermore, the use of pain medication was negatively associated with physical well-being in pre-dialysis ADPKD patients [25] . Anxiety, depression and chronic pain may lead to a decrease in quality of life [24] . In the management of chronic pain, the presence of anxiety or depression should therefore be investigated, and, when present, adequately treated.
Paramount to the understanding of the sensory nerve supply of visceral organs is that visceral afferent fibers travel via visceral efferent pathways. Thus, in general, sensory innervation of internal organs is described in terms of efferent, i.e. sympathetic and parasympathetic fibres. It should be emphasized, however, that all efferent pathways contain visceral afferents, including nociceptive fibres. Except for nociception from the pelvis floor organs, nociception from all internal organs traverse via sympathetic pathways to the spinal cord and, consequently, end in the spinal cord segments C8-L1 [26] . Referral of visceral pain to dermatomal areas depends on the level of segmental innervations. Thus, e.g. pain felt in dermatomal area T10 can derive from any ( part of ) internal organ that projects its nociceptive impulses to spinal cord segment T10 [26, 27] .
The sensory nerve supply of the upper abdominal organs via sympathetic and parasympathetic fibres [26] is schematically depicted in Figure 1 . Pain originating from the kidney and upper abdominal organs reaches the lower thoracic spinal cord via the celiac and aorticorenal plexus, the major splanchnic nerve (T5-9, upper abdominal organs including liver) [28, 29] , the lesser splanchnic nerve (T10-11, renal parenchyma and ureter) [29] , the least splanchnic nerve (T12-L1, renal capsule) [29] and finally the sympathetic trunk.
The major splanchnic nerves terminate in the celiac plexus, formed by the left and right celiac ganglion and interconnecting nerve fibres. Its location and extent make it an effective target for invasive pain therapy by blockade by alcohol or phenol injection. A celiac plexus block has been applied for many years, especially for oncological upper abdominal pain [30] . The lesser and least splanchnic nerves travel via the aorticorenal plexus to their target organ. This makes it technically much more difficult to obtain an effective and selective blockade. In contrast, in celiac blocks overflow to the aorticorenal plexus might not be overcome.
Parasympathetic fibres to the kidney originate from the vagus nerve. They traverse through the celiac plexus or pass directly to the aorticorenal plexus [28] . They end upon solely to the smooth muscles of the renal pelvis and calyces, but do not supply the renal parenchyma nor the renal capsule. In trying to determine the original source of pain, a practical approach would be to 'follow the dermatome where the pain is felt'. This means, that when pain is referred to dermatomes T5 and T6, the most plausible route is via the celiac plexus and major splanchnic nerve (including all other organs supplied by T5 and T6). When the pain is referred to dermatomes T11-12, consequently the lesser and least splanchnic nerve may be the pathways including, again, all other organs that project to T11 and T12. Given the above, analysis of the dermatomes, where the (visceral) pain is referred to, should be part of the investigation of possible causes of chronic pain in ADPKD, because it may help the decision-making process which (invasive) pain therapy to consider.
P OT E N T I A L T R E AT M E N T O P T I O N S FO R C H RO N I C PA I N I N A D P K D
Literature search An electronic literature search was performed up and until 28 December 2013, to obtain a complete overview of treatment options for chronic pain in ADPKD. For this literature review, PubMed was searched using the string: [('ADPKD' OR 'polycystic kidney disease' OR 'polycystic liver disease' OR 'PLD') AND ('pain')]. Obtained manuscripts were searched for crossreferences, and experts in the field were consulted to identify all relevant articles. This search yielded a total of 419 articles. Articles that were left after removal of duplicates and title and abstract screening for eligibility were critically appraised whether interventions were performed for pain as indication. 
Nonpharmacological therapies
Since chronic pain is a composite of physical and psychophysical derangements, management should incorporate both aspects to be successful. Nonpharmacological therapies include therefore a wide range of options that may be divided into physical interventions (including physical therapy, massage and ice and heat pads) and psycho-educational interventions (for example patient education, cognitive-behavioural therapy or psychotherapy). In the general population psycho-educational interventions are the cornerstone for modern pain management practice in patients with chronic pain. These treatment options should also be discussed with ADPKD patients with chronic pain and can often lead to effective pain reduction. However, to our knowledge, the effectiveness of these interventions has never been investigated in specifically ADPKD patients.
The two previous reviews on pain management in ADPKD discussed the Alexander technique [8, 22] . This is a nonexercise approach to improve the natural body posture, and patients learn how to move and position their body to reduce pain. This technique may also help ADPKD patients, especially when musculoskeletal pain due to aberrant posture is the main cause of pain, although we are not aware of studies that test the efficacy of the Alexander technique in specifically ADPKD patients. 
Pharmacological therapies Causal treatment. As yet no treatment options are available to modify the course of disease progression in ADPKD. However, there are recent interesting developments. The TEMPO 3:4 trial found that the vasopressin V2 receptor antagonist tolvaptan slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD. In addition, Tolvaptan use was associated with pain reduction [3, 4] , and the frequency of acute pain events was significantly lower in the treatment arm [3] . Interestingly, tolvaptan was also associated with a significant lower incidence of reported chronic kidney pain. Somatostatin analogues offer another therapeutic option. Recent clinical trials found that octreotide and lanreotide reduced the growth rates of the liver as well as kidneys [31] [32] [33] , with benefits in terms of perception to health to ADPKD patients. The above data suggest a beneficial effect on the incidence and prevalence of pain by agents slowing disease progression in ADPKD. Unfortunately, vasopressin V2 receptor antagonists as well as somatostatin analogues are not yet available for clinical use in ADPKD subjects [3, 4] . Current pharmacological treatment options for the management of chronic pain are therefore symptomatic.
Symptomatic treatment. The World Health Organization defined a three-step analgesic ladder to describe its guideline for the use of drugs in the management of pain. It was originally applied to the management of cancer pain, but is now widely used by medical professionals for the management of all types of pain including that in renal patients [34] . The drugs that may be prescribed are, first, acetaminophen ( paracetamol) with or without adjuvant therapy. Adjuvants are used for enhancing the efficacy of pain medication, controlling side effects or managing other symptoms that may be associated with pain. Second, in case pain is insufficiently relieved, nonsteroidal anti-inflammatory drugs (NSAIDs) or mild opioids, (e.g. tramadol), both with or without adjuvants, can be tried. Because of their renal haemodynamic effects and nephrotoxicity, NSAIDs are not recommended in ADPKD patients with impaired kidney function. Before opioids are given, combination therapy of acetaminophen with NSAIDS can be tried, which may lead to effective pain therapy and avoid the use of opioids. Thirdly, when combination therapy did not provide sufficient pain relief, strong opioids (e.g. morphine), with or without adjuvants, can be given. Analgesics should be given in a fixed dose schedule, since pain medication is most effective when a steady blood level of pain medication is obtained. The dose of these analgesics varies between patients and is identified as the dosage needed to relieve pain without producing intolerable side effects. Patients should be aware of especially the potential side effects of opioids, such as constipation, nausea, vomiting, sedation and mental changes, as well as that this medication can lead to habituation and addiction. Opioids can be given via several routes, but the best evidence for efficacy applies to the transdermal route [35] . Caution is needed when using opioids in patients with a GFR < 30 mL/min or end-stage renal disease. Because of retention due to decreased renal clearance of pharmacologically active metabolites, these drugs can result in considerable side effects. This three-step approach of administering analgesics is inexpensive and in 80-90% of patients effective [34] .
Of note, sometimes also anti-epileptics (e.g. pregabalin or gabapentin) and antidepressants (e.g. amitryptiline or nortryptiline) are prescribed to ADPKD patients with success, although these medications for neuropathic pain have never been formally investigated for pain related to ADPKD.
Minimal invasive pain therapies
Celiac and splanchnic nerve block. Renal pain related to compression of adjacent tissue can be successfully treated by celiac nerve block. Injecting neurolytic agents like alcohol or phenol destroys nerve fibres within the celiac plexus, by which the pain pathway of the upper abdominal organs including the liver is blocked. A celiac block has been used for chronic intractable abdominal pain related to cancer, in particular pancreatic, gastric and intestinal cancer [36] and in paediatric patients for pain related to compression by neuroblastoma and hepatoblastoma [37, 38] . Success rates in cancer vary between 70 and 100% [36, 39] .
A temporary celiac block by short acting local anesthetics may help differentiate between pain caused by distension of the renal capsule and compression of adjacent tissue. When a celiac block is effective and results in complete pain relief, the pain is probably caused by compression of adjacent visceral tissue. If no pain relief is observed, it may suggest that the pain is related to distension of the renal capsule (where pain follows another pathway, see Figure 1 ).
As the liver and liver capsules are supplied by visceral afferent nerves via the celiac plexus, interventions that block this plexus may relieve liver pain in ADPKD [40] . Indeed, one case report showed that liver capsule pain after blunt trauma can be managed by a paravertebral block at the T10 level [40] . However, in this case more nervous structures are blocked, such as the sympathetic trunk and the lower thoracic spinal nerves. We could not identify studies that describe similar therapies in patients with hepatic cystic disease.
When a celiac nerve block cannot be performed, a splanchnic nerve block can be an alternative treatment option. Traditionally, neurolysis with 10 mL of absolute alcohol or 6-10% phenol has been performed [41] . However, the difficulty in dividing the agent within the anatomical compartment of the splanchnic nerves with a chance of nerve root damage, is considered a disadvantage of this block [42] . Radiofrequency thermal coagulation might be a useful alternative method [42] .
Although, at present, neurolytic blocks are not often applied in chronic ADPKD related pain, they deserve, in our opinion, a prominent place in the stepwise approach for chronic pain related to ADPKD.
Renal denervation. The renal nerves, carrying both sympathetic efferent and sensory afferent nerve fibres, are circumferentially distributed in the adventitia around the renal artery. Renal denervation has been proposed for patients with intractable ADPKD-related pain that is caused by distension of the renal capsule and may be a good alternative for the various surgical procedures that are described below. Table 1 shows an overview of studies that investigated renal denervation in patients with ADPKD. Three case reports describe thoracoscopic or laparoscopic procedures, leading to excellent pain control [43] [44] [45] . However, these invasive techniques are difficult to perform, and require surgical experience, which is difficult to obtain given the limited number of patients with intractable ADPKD-related pain. Recently a catheter-based percutaneous transluminal method has been introduced. By applying high frequency energy, adjacent tissue is coagulated resulting in ablation of efferent and afferent renal nerve fibers. This procedure is now mainly applied for blood pressure control in patients with therapy resistant hypertension. We applied this procedure in an ADPKD patient with intractable pain likely to be related to the large polycystic kidneys and in whom oral analgesics did not result in effective pain treatment [46] . Following this procedure, the patient was completely free of pain. Although from a theoretical point of view catheterbased renal ablation of renal sensory nerves is an attractive option in selected cases, additional reports on efficacy are awaited before its exact place in the management of chronic pain in ADPKD patients can be determined.
Transcutaneous electrical nerve stimulation and spinal cord stimulation. For transcutaneous electrical nerve stimulation (TENS) small electrodes are placed on the cutaneous receptive fields of somatic sensory nerve fibers that project to the same spinal cord segments as the involved visceral afferents. By electrical stimulation of giving continuous electrical impulses, the responsiveness of pain fibers is reduced which leads to a decreased stimulus to the dorsal horn cells, resulting in a decrease in pain sensation. At the moment, particularly in patients with low back pain TENS is used. To our knowledge no report has been published on the effectiveness of TENS for ADPKD related chronic pain.
Spinal cord stimulation is an alternative analgesic technique, which has been performed for pain related to cancer [47] . It has become fashionable for treatment of chronic intractable pain, especially from neuropathic origin [48] . This technique uses electrodes placed in the epidural space to modulate pain pathways. One case report described a patient with uncontrolled severe chronic pain related to renal cysts with complete pain relief after spinal cord stimulation [49] .
All aforementioned nonpharmacological pain therapies have been described thus far only in case reports. Elucidating their efficacy and their place within the treatment algorithm for ADPKD related chronic pain should be part of the research agenda.
Invasive therapies for renal and hepatic cysts Renal cyst aspiration, sclerotherapy and fenestration. Table 2 shows an overview of studies that investigated renal cyst aspiration, sclerotherapy and fenestration as treatment options for ADPKD related pain [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] .
In 1987 percutaneous renal cyst aspiration was first described in a study of 11 patients [57] . Pain improved in most patients, but after 18 months only 33% of the patients had sufficient pain relief. This may be caused because after aspiration, fluid secretion causes cysts to re-appear. Later studies, mainly from Asia, injected cysts with ethanol, minocycline hydrochloride, N-butyl cyanoacrylate or iodized oil after aspiration are were more effective in preventing cyst re-appearance [58, 60, 64] . This seems to be associated with a higher success rate, but unfortunately also comes with limited pain control. Furthermore, percutaneous aspiration may be difficult, because it is often not known which cyst causes pain.
With renal cyst fenestration or marsupialization, cysts can also be drained to prevent their re-appearance. This procedure is invasive and can be performed in the case of extremely large cysts, where they have been shown to be effective. The kidney is approached, either laparoscopically or by open procedure, and the renal capsule is opened and cysts are unroofed. Bleeding can occur, but is in general easily controlled by coagulation. Cysts that are drained should not communicate with the peritoneal cavity to avoid infection. The immediate success rate is very high and varies between 85 and 90%, but 1-2 years follow-up showed a decrease in success rate to ∼65% [53, 54] and severe complications have been observed.
Given the uncertain success rate and common complications we advise to be reluctant with performing renal cyst aspiration, sclerotherapy or fenestration for pain management.
Liver cyst aspiration, sclerotherapy and fenestration. Similar as in renal cysts, aspiration with sclerotherapy or cyst fenestration can be performed for relief of liver cyst associated pain [65] .
Aspiration-sclerotherapy is the preferential treatment for a dominant cyst >5 cm that can be reached percutaneously. Table 3 shows an overview of studies that evaluated the effect of cyst aspiration-sclerotherapy on liver-related pain [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] . Ethanol was the most commonly used sclerosing agent. In contrast to the situation for renal cysts, most studies demonstrated high rates of pain relief after aspiration-sclerotherapy of hepatic cysts. However, outcomes were less favourable in patients with polycystic livers compared with those with solitary cysts [76, 77] . Therefore, we do not recommend this therapy for ADPKD patients with severe polycystic livers except in cases where there is a large accessible anterior hepatic segment cyst(s) that appears to correlate with patient symptoms.
Hepatic fenestration involves surgical deroofing of multiple large cysts in order to reduce liver volume and ameliorate symptoms [79] . Results on pain relief after hepatic cyst fenestration are shown in Table 4 [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] . Although immediate pain relief was achieved in almost all patients, pain recurrence occurred in up to 62% of treated patients [80, 83, 86] . Furthermore, the procedure is associated with several complications, including ascites, pleural effusion, arterial or venous bleeding and biliary leakage although these complications are much more infrequent with adoption of laparoscopic fenestration techniques as opposed to laparotomy [65, 92] . Again, patients with severe polycystic livers, characterized by numerous small liver cysts, had worse outcomes than patients with single of multiple large liver cysts. Therefore, hepatic fenestration is only a viable option for patients who are highly symptomatic and have one or more large liver cysts accessible by laparoscopy [91] .
Nephrectomy, renal coiling, partial hepatectomy and liver transplantation. Nephrectomy and renal coiling are last resort options. In patients with preserved renal function it is a difficult decision to remove a functioning kidney knowing that ADPKD may lead to renal failure. The options should therefore be reserved for patients that are pre-end-stage renal disease or those already receiving renal replacement therapy.
Nephrectomy leads to some or even complete pain relief, but such an intervention is not without risks [93] [94] [95] [96] [97] [98] [99] [100] . Major complications that have been reported include retroperitoneal haematoma, incisional hernias and arteriovenous fistula [95, [97] [98] [99] . In general, the removal of large polycystic kidneys may be safely accomplished via laparoscopy instead of open surgery, but sometimes conversion to open surgery is necessary [101] . The benefits of laparoscopic surgery are decreased postoperative pain, less blood loss, shorter hospitalization and a better cosmetic result when compared with the open procedure [101] . Hand-assisted laparoscopic techniques (unilateral or bilateral) have been shown to be safe, associated with reduced morbidity [100, 102] , and facilitates the resection of the massively enlarged polycystic kidney through a smaller incision than traditional simple or radical nephrectomy approaches. Laparoscopic nephrectomy has been performed safely bilateral and even in combination with allograft placement [103] .
Renal artery coiling is indicated especially for patients with severe pain and contraindications to surgical interventions. A steel or platinum coil is placed into the main renal arteries to obstruct blood supply. The effectiveness of coiling is reported to be 53-60% for pain relief following this procedure [64, 104] . When coiling fails, other techniques such as alcohol injection or gelatin sponges can be used. However the experience with these latter interventions is limited [105] . Severe complications after renal coiling are possible in situations where for instance adrenal, gonadal and phrenic branches of the renal arteries exist or when there is incorrect catheter placement.
Partial hepatectomy is performed in patients with severe hepatomegaly with at least one liver segment without liver cysts [92] . While 86% of patients experience relief of symptoms, including pain, this procedure is associated with considerable morbidity (63%) and mortality (3%) [65] . Furthermore, adhesions might complicate future liver or kidney transplantation. Therefore, we only recommend this option in patients, in which the liver cysts are mainly presented in one liver segment.
Liver transplantation is the last option for liver pain management, only indicated in patients with extremely impaired quality of life due severely disabling symptoms and diffuse cystic disease [65] . This option should be weighed carefully in view of the associated morbidity and organ shortage, especially because liver synthetic capacity remains normal even in advanced polycystic liver disease [106] .
S U G G E S T E D A P P R OAC H FO R E VA L U AT I O N A N D T R E AT M E N T O F C H R O N I C PA I N I N A D P K D
In Figure 2 we present our approach to patients with ADPKD and chronic pain. The first step is to exclude non-ADPKD related sources of pain, which should be treated as normal. Treatment of non-ADPKD related somatic pain or neuropathic pain is beyond the scope of this review.
In ADPKD patients the prevalence of symptoms of depression and anxiety is higher than in the general population. In management of chronic pain, the presence of depression should be investigated. When depression is diagnosed, adequate management is necessary with medication (e.g. antidepressants) and/or psychotherapy.
When pain is considered to be related to the cystic kidneys or liver, subacute or prolonged courses of acute kidney pain must be considered, such as cyst haemorrhage, cyst infection and urinary tract stones. Careful anamnesis and physical examination should trigger to these possibilities and additional laboratory tests and imaging should be performed on indication. Imaging studies may be of limited value in this respect because ultrasound, CT and MRI can often not distinguish between infected cysts and asymptomatic or haemorrhaged cysts [15] . FDG-PET scan has the best performance in detecting a cyst infection.
The next step is to consider the possibility of aberrant posture or motion, which can lead to pain due to increased or abnormal muscle tension. These subjects are most likely to benefit from physiotherapy (such as the Alexander technique) and should not receive any invasive treatment. Management in cases where there is intractable pain should be based on an interdisciplinary approach consisting of both pain physicians and nephrologists. All subjects with chronic pain should be advised first to try conservative methods for pain reduction, these are behavioural methods (for example cognitive-behavioural therapy) and try ice/heat pads, before invasive therapies are considered. In many patients these conservative interventions, may lead to effective pain relief.
When these methods are inadequate, pharmacological treatment can be considered, starting with acetaminophen, adding the mild opioid tramadol on indication and, when not effective enough, replace tramadol for hydrocodone, oxycodone, other opiates such as buprenorphine or fentanyl patch or in some refractory cases, oral or transdermal morphine. Adjuvants may be added when needed, for example, a laxative should be added to opioids in order to avoid constipation, which in our experience occurs more often in ADPKD than in non-ADPKD patients.
When conservative and pharmacological strategies are ineffective, more invasive methods can be considered. The most subtle and probably most effective method is to perform a neurolytic block of the sensory nerves that are involved. For this purpose it is important to distinguish between pain deriving from tension of the renal capsule, which is innervated via the least splanchnic nerve, and pain due to compression of adjacent tissue (including the liver), which leads to visceral pain via the celiac plexus. Anamnesis, (including analysis of the dermatomes of referred visceral pain), physical examination and imaging may help to discriminate between these two types of pain. However, often this is not sufficiently possible. In such cases a temporary celiac nerve block can be used as test procedure. Subsequently a long-term plexus block can be given when pain is considered to be due to compression of adjacent tissue. When pain is believed to be caused by distension of the renal capsule we suggest considering renal denervation, which should be effective from a theoretical point of view, although further experience with this technique is awaited. Other experimental interventions that may have a place in management of chronic pain in ADPKD are transcutaneous electrical nerve and spinal cord stimulation [49] .
More invasive methods can be considered only as a last step. Due to limited effects in patients with ADPKD we do not recommend cyst aspiration. Cyst fenestration is a method with better long-term results and can be considered, especially in settings where preservation of residual renal function is important and when there are a limited number of very large cysts. However, complications are relatively common and pain relief was only achieved in ∼60% of subjects. Nephrectomy is associated with major complications and obviously any residual renal function will be lost. Therefore, a nephrectomy should be considered as a last resort, and be reserved for especially patients receiving renal replacement therapy. Embolization of the renal artery, with the same disadvantage of losing kidney function, is a technique with variable technical success rate. When successful, promising results with respect pain relief can be obtained, while no major complications have been reported. Laparoscopic fenestration, partial hepatectomy or liver transplantation can be performed in case of severe, untreatable chronic pain related to liver cysts. Partial hepatectomy is especially indicated in patients, in which the liver cysts are mainly presented in one liver segment. Because of the associated morbidity and mortality liver transplantation is only indicated in patients with extremely impaired quality of life.
CO N C L U S I O N S
Chronic pain in ADPKD is abdominal or loin pain in the kidney or liver region that exists for >4-6 weeks. It affects >60% of ADPKD patients, and can have serious negative impact on physical and social functioning. Careful assessment by obtaining a detailed history and physical examination along with imaging techniques are necessary to identify the cause of F I G U R E 2 : Proposed management algorithm for chronic pain in ADPKD patients, starting with measures that are nonpharmacological, progressing to pharmacological, minimal invasive and ultimately to complex, invasive therapies.
pain, and interventions should be directed towards these causes. A stepwise approach for pain management according to a treatment algorithm as proposed in this review may be of help to achieve successful pain relief in ADPKD patients.
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